Lanreotide acetate sustained-release composition as well as preparation method and application thereof

The preparation process is simplified by the reduced pressure concentration method of lanreotide acetate, solving the problems of complex and costly preparation in the prior art, and improving the uniformity and release effect of the lanreotide acetate sustained-release composition.

CN119015395APending Publication Date: 2024-11-26SICHUAN HUIYU PHARMA
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411162398.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing preparation methods of lanriotept acetate sustained-release preparation are complex, requiring freeze-drying and hydration steps, resulting in high production costs, high operation difficulty, long production cycle, and poor mixing uniformity.

Method used

The preparation process is simplified by dissolving lanriotide acetate in water and concentrated under reduced pressure until the target concentration is reached, forming a semi-solid viscous gel-like condition, and uniformity and cost reduction are achieved through filtration and vacuum concentration.

Benefits of technology

The uniformity of the lanriotept acetate sustained-release composition is achieved, with simplified operation, reduced cost and shortened production cycle, and the release effect is consistent with the original research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005006816480000011
    Figure BDA0005006816480000011
  • Figure BDA0005006816480000071
    Figure BDA0005006816480000071
  • Figure BDA0005006816480000081
    Figure BDA0005006816480000081
Patent Text Reader

Abstract

The invention discloses a lanreotide acetate sustained-release composition as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention provides a lanreotide acetate sustained-release composition and a preparation method and application thereof, and the preparation method comprises the following steps: dissolving lanreotide acetate in water to prepare an aqueous solution, and carrying out vacuum concentration on the obtained aqueous solution until the concentration of lanreotide free alkali is 20-28% (w / w). Compared with the prior art, the preparation method disclosed by the invention is simple, the time cost and the production cost are reduced, and meanwhile, the lanreotide acetate sustained-release composition prepared by adopting the method disclosed by the invention is better in uniformity; on the basis of simplifying the operation steps, the lanreotide acetate sustained-release composition prepared by the method has the same release effect as the original lanreotide acetate sustained-release composition.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a lanreotide acetate sustained-release composition and a preparation method and application thereof, belonging to the technical field of medicines. Background Art

[0002] Lanreotide acetate is an octapeptide analogue of natural somatostatin developed by IPSEN PHARMA, France. Its molecular formula is C 54 H 69 N 11 O 10 S2(CH3COOH)x(x=1.0~2.0), the molecular weight of pure peptide is 1096.34 (free base). Lanreotide acetate is an inhibitor of various endocrine, neuroendocrine, exocrine and paracrine functions. It is clinically used to treat acromegaly, gastrointestinal pancreatic neuroendocrine tumors and syndromes caused by neuroendocrine tumors (especially carcinoid tumor syndrome). Its structural formula is shown below:

[0003]

[0004] x(CH3COOH), where x = 1.0 to 2.0

[0005] The currently marketed lanreotide acetate preparation is lanreotide acetate sustained-release injection (prefilled), which is a supersaturated semisolid gel containing 24.6% (by weight) lanreotide free base, with a viscosity of more than 10,000 Pa·s, and is injected subcutaneously once every 28 days. The trade name is Somatuline Autogel. Due to the extremely high viscosity of the lanreotide acetate semisolid sustained-release injection, it cannot be prepared by conventional mechanical stirring.

[0006] Patents CN102711728B and CN105456206B disclose a method for preparing a pharmaceutical composition for delayed release of somatostatin analogs, wherein lanreotide is first mixed with an acid aqueous solution, the obtained mixture is freeze-dried once, and then the freeze-dried product is added with water to prepare a viscous lanreotide acetate semisolid sustained-release preparation. International patent WO 99 / 48517 discloses a solid or semisolid pharmaceutical composition containing a gelling and water-soluble peptide salt, wherein the method comprises first dissolving lanreotide in water, then rapidly freezing the solution with liquid nitrogen, then freeze-drying, and finally adding water to the freeze-dried product to prepare a semisolid viscous sustained-release preparation.

[0007] The above-mentioned prior art is to first dissolve lanreotide acetate and then freeze-dry, and then add water to the lyophilized material to make a sustained-release preparation. This method has many defects. First, the freeze-drying operation is more complicated, and special equipment needs to be configured, resulting in a significant increase in production costs. Secondly, after the lyophilized material is prepared, it is also necessary to go through a hydration step, that is, the lyophilized material and water are mixed by a piston reciprocating extrusion between two containers, so as to prepare a semi-solid sustained-release preparation with great viscosity. Due to the fact that the material is not fully wetted during the mixing process, especially in the initial stage of mixing, the dry material causes a great difficulty in the reciprocating extrusion operation, and the force of the extrusion push rod often reaches more than 50000N, and it is also difficult to ensure that the mixing is uniform, and this operation process is extremely cumbersome, especially in mass production, if mixing is to be fully achieved, more operable equipment is needed, which greatly increases the production cost. In addition, the production cycle using the above method is also relatively long.

[0008] Therefore, there is an urgent need to develop a method for preparing a lanreotide acetate sustained-release composition with simple operation, reduced cost, better uniformity of prepared products, and shortened production cycle. Summary of the invention

[0009] The present invention aims to solve at least one of the technical problems existing in the prior art. To this end, one of the objects of the present invention is to provide a method for preparing a lanreotide acetate sustained-release composition. Another object of the present invention is to provide the use of the lanreotide acetate sustained-release composition.

[0010] The invention provides a method for preparing a lanreotide acetate sustained-release composition, comprising the following steps: a. dissolving lanreotide acetate in water to obtain an aqueous solution; b. concentrating the aqueous solution obtained in step a under reduced pressure until the concentration is 20-28% (w / w) based on lanreotide free base.

[0011] Furthermore, in step b, the mixture is concentrated to a concentration of 23% to 26% (w / w) based on lanreotide free base.

[0012] Preferably, step b is concentrated to a concentration of 24.6%, w / w, based on lanreotide free base.

[0013] Furthermore, in step b, the aqueous solution is concentrated into a semisolid viscous gel state.

[0014] Furthermore, the aqueous solution obtained in step a has a concentration of 18 to 22 mg / ml based on lanreotide free base.

[0015] Preferably, the aqueous solution obtained in step a has a concentration of 20 mg / ml based on lanreotide free base.

[0016] Furthermore, the vacuum degree of reduced pressure concentration in step b is 30-100Pa.

[0017] Preferably, the vacuum degree of reduced pressure concentration in step b is 50Pa.

[0018] Furthermore, step b is concentrated under reduced pressure at 30-70°C.

[0019] Preferably, step b is concentrated under reduced pressure at 40-60°C.

[0020] More preferably, step b is concentrated under reduced pressure at 50°C.

[0021] Furthermore, before step b, the method further comprises the step of filtering the aqueous solution obtained in step a.

[0022] Preferably, two stages of 0.22 μm sterilizing filters are used for filtration.

[0023] The present invention also provides a lanreotide acetate sustained-release composition obtained according to the above-mentioned preparation method.

[0024] The present invention also provides use of the lanreotide acetate sustained-release composition obtained according to the above-mentioned preparation method in preparing injections.

[0025] Preferably, the injection is a subcutaneous injection.

[0026] The present invention also provides use of the lanreotide acetate sustained-release composition obtained according to the above-mentioned preparation method in preparing a drug for treating acromegaly or gastrointestinal pancreatic neuroendocrine tumors or carcinoid syndrome.

[0027] The present invention provides a method for preparing a lanreotide acetate sustained-release composition, which has at least the following beneficial technical effects:

[0028] 1. Compared with the prior art, the lanreotide acetate sustained-release composition prepared by the method of the present invention has better uniformity.

[0029] 2. On the basis of simplifying the operation steps, the release effect of the lanreotide acetate sustained-release composition prepared by the method of the present invention is consistent with that of the original research.

[0030] 3. Compared with the prior art, the preparation method of the present invention is simple, which reduces time cost and production cost. DETAILED DESCRIPTION

[0031] The scheme of the present invention will be further described below by specific implementation methods and experiments. It will be appreciated by those skilled in the art that the following examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the examples, the techniques or conditions described in the literature in this area or the product instructions are used. The reagents or instruments used that do not indicate the manufacturer are all conventional products that can be obtained commercially.

[0032] Sources of raw materials and equipment:

[0033] Aseptic weighing material tank: Shanghai Dongfulong Technology Co., Ltd.;

[0034] The original marketed preparation of lanreotide acetate (trade name: somadulin): IPSEN PHARMA, batch number U01955.

[0035] Example 1 Preparation of Lanreotide Acetate Sustained-Release Composition

[0036] The method of the present invention is used to prepare a lanreotide acetate sustained-release composition having a concentration of 23% (w / w, based on lanreotide free base), and the steps are as follows:

[0037] (1) dissolving 492 g of lanreotide acetate (calculated as lanreotide free base) in water for injection to prepare a drug solution with a concentration of 20 mg / ml (calculated as lanreotide free base);

[0038] (2) Filter the drug solution obtained in step (1) through two stages of 0.22 μm sterilizing filters, transfer the filtered drug solution into a sterile weighing material tank, and record the weight of the filtered drug solution;

[0039] (3) The sterile weighing material tank is evacuated to 50 Pa and heated to 40° C. for vacuum concentration. The weight loss of the sterile material tank is recorded in real time during the vacuum concentration process. When the concentration is calculated to be 23% (w / w, based on lanreotide free base) by the weight loss, the vacuum concentration is stopped to obtain the target product;

[0040] (4) Fill the target product obtained in step (3) into a 1 ml prefilled syringe.

[0041] The target product prepared by the method of Example 1 is in the form of a semi-solid viscous gel, and the required time is 29 hours.

[0042] Example 2 Preparation of Lanreotide Acetate Sustained Release Composition

[0043] The method of the present invention is used to prepare a lanreotide acetate sustained-release composition having a concentration of 24.6% (w / w, based on lanreotide free base), and the steps are as follows:

[0044] (1) dissolving 492 g of lanreotide acetate (calculated as lanreotide free base) in water for injection to prepare a drug solution with a concentration of 20 mg / ml (calculated as lanreotide free base);

[0045] (2) Filter the drug solution obtained in step (1) through two stages of 0.22 μm sterilizing filters, transfer the filtered drug solution into a sterile weighing material tank, and record the weight of the filtered drug solution;

[0046] (3) The sterile weighing material tank is evacuated to 50 Pa and heated to 50° C. for vacuum concentration. The weight loss of the material tank is recorded in real time during the vacuum concentration process. When the concentration is calculated to be 24.6% (w / w, based on lanreotide free base) by the weight loss, the vacuum concentration is stopped to obtain the target product;

[0047] (4) Fill the target product obtained in step (3) into a 1 ml prefilled syringe.

[0048] The target product prepared by the method of Example 2 is in the form of a semisolid viscous gel, and the required time is 25 hours.

[0049] Example 3 Preparation of Lanreotide Acetate Sustained Release Composition

[0050] The method of the present invention is used to prepare a lanreotide acetate sustained-release composition having a concentration of 26% (w / w, based on lanreotide free base), and the steps are as follows:

[0051] (1) dissolving 492 g of lanreotide acetate (calculated as lanreotide free base) in water for injection to prepare a drug solution with a concentration of 20 mg / ml (calculated as lanreotide free base);

[0052] (2) Filter the drug solution obtained in step (1) through two stages of 0.22 μm sterilizing filters, transfer the filtered drug solution into a sterile weighing material tank, and record the weight of the filtered drug solution;

[0053] (3) The sterile weighing material tank is evacuated to 50 Pa and heated to 60° C. for vacuum concentration. The weight loss of the material tank is recorded in real time during the vacuum concentration process. When the concentration is calculated to be 26% (w / w, based on lanreotide free base) by the weight loss, the vacuum concentration is stopped to obtain the target product;

[0054] (4) Fill the target product obtained in step (3) into a 1 ml prefilled syringe.

[0055] The target product prepared by the method of Example 3 is in the form of a semisolid viscous gel, and the required time is 23 hours.

[0056] Comparative Example 1: Preparation of Lanreotide Acetate Sustained-Release Composition Using the Method of Patent CN102711728B

[0057] (1) 492 g of lanreotide acetate (calculated as lanreotide free base) was dissolved in an aqueous solution of acetic acid with a concentration of 15% (w / w), and the resulting solution was placed in a stainless steel freeze-drying tray, cooled from room temperature to 2°C within 10 minutes, and then kept at this temperature for 3 hours, and then the cooled mixture was frozen to -40°C within 10 minutes, and then kept at this temperature for 2.75 hours. Thereafter, the mixture was heated from -40°C to 25°C under a vacuum condition of 20 μbar within 20 hours, and then heated to 35°C and kept for 16.75 hours;

[0058] (2) The water for injection is acidified with glacial acetic acid (the amount of glacial acetic acid used is sufficient to make the content of anhydrous acetate in the target product 9.6% to 10% (w / w)), and finally the acidified water for injection and lanreotide acetate are hydrated, and then reciprocated to obtain a lanreotide acetate sustained-release composition with a concentration of 24.6% (w / w, based on lanreotide free base). The specific steps are as follows: lanreotide acetate and acidified water for injection are weighed and placed in two different stainless steel barrels, respectively. The stainless steel barrels are equipped with pistons and connected by three-way valves. Before hydration, water is introduced into the stainless steel barrel containing lanreotide acetate through the three-way valve, and then the lanreotide acetate is statically hydrated for at least 2 hours. Then, the piston is used to make the contents reciprocate back and forth between the two stainless steel barrels, so that the dispersion is evenly distributed, and finally a supersaturated gel of lanreotide acetate with a pH of 6.2 is obtained, which is filled into a 1 ml prefilled syringe.

[0059] In general, the above method is to first mix lanreotide acetate with an acid aqueous solution, freeze-dry the obtained mixture once, and then add water to the freeze-dried product through a hydration step to finally prepare a lanreotide acetate sustained-release preparation in a semisolid viscous form, and the required time is 52.8 hours.

[0060] It can be seen from the above steps that the freeze-drying operation is relatively complicated and requires the configuration of special equipment, which will lead to a significant increase in production costs, and the cycle for preparing the target product using the above method is also relatively long; in addition, after the freeze-dried material is prepared by the above method, it is necessary to go through a hydration step, that is, the freeze-dried material and water are mixed by reciprocating piston extrusion between two containers. However, since the materials are not completely wetted during the mixing process, especially in the initial mixing stage, the reciprocating extrusion operation of the dry materials is very difficult, and the force of the extrusion push rod often reaches more than 50,000N. At the same time, it is difficult to ensure uniform mixing, and this operation process is extremely cumbersome, especially in mass production. If you want to fully achieve mixing, you need more operational equipment, which greatly increases the production cost.

[0061] Comparative Example 2: Preparation of Lanreotide Acetate Sustained-Release Composition Using the Method of Patent WO1999048517A1

[0062] (1) 492 g of lanreotide acetate (calculated as lanreotide free base) was dissolved in 9840 ml of water. The resulting solution was atomized by a sprayer and then sprayed into a stainless steel plate (the bottom of the stainless steel plate was immersed in liquid nitrogen for cooling). After the product was frozen, the stainless steel plate was transferred to a freeze dryer with a shelf temperature of about -54°C. The temperature of the product and the freeze drying plate was kept balanced for 1 hour, and then the sublimation stage was entered (the shelf temperature was set at 20°C and the pressure was set at 100 μbar). This stage lasted for about 30 hours. When the temperature of the product reached about 13°C, secondary drying was entered and the pressure was adjusted to 50 μbar for 24 hours. The final temperature of the product was about 20°C.

[0063] (2) Collect the powder obtained after freeze-drying in step (1), add water and mix according to the following steps to obtain a lanreotide acetate sustained-release semisolid preparation with a concentration of 24.6% (w / w, based on lanreotide free base): weigh the freeze-dried lanreotide acetate and water, respectively place them in two different stainless steel barrels, the stainless steel barrels are equipped with pistons and connected by three-way valves, and before hydration, introduce water into the stainless steel barrel containing lanreotide acetate through the three-way valve to allow the lanreotide acetate to be statically hydrated for at least 2 hours, and then use the piston to make the contents reciprocate and squeeze between the two stainless steel barrels to make the dispersion uniformly distributed, and finally obtain a supersaturated gel of lanreotide acetate with a concentration of 24.6% (w / w, based on lanreotide free base), which is filled into a 1 ml prefilled syringe.

[0064] In general, the above method is to first dissolve lanreotide acetate in water, then quickly freeze the solution with liquid nitrogen, then freeze-dry it, and finally add water to the freeze-dried product to prepare a semi-solid viscous lanreotide acetate sustained-release preparation, which takes 66 hours.

[0065] The above method also needs to go through a freeze-drying step, which is relatively complicated to operate and requires the configuration of special equipment, which will lead to a significant increase in production costs, and the cycle for preparing the target product using the above method is also relatively long; in addition, after the freeze-dried material is prepared by the above method, it is also necessary to go through a hydration step, that is, the freeze-dried material and water are mixed by reciprocating piston extrusion between two containers, but because the materials are not completely wetted during the mixing process, especially in the initial mixing stage, the dry materials make the reciprocating extrusion operation very difficult, and the force of the extrusion push rod often reaches more than 50,000N. At the same time, it is also difficult to ensure uniform mixing, and this operation process is extremely cumbersome, especially in mass production. If you want to fully achieve mixing, you need more operational equipment, which greatly increases the production cost.

[0066] Verification experiment example

[0067] 1. Uniformity inspection

[0068] Ten samples prepared according to the methods of Examples 1 to 3 and Comparative Examples 1 to 2 were taken respectively, and the concentration of lanreotide in each sample was detected by high performance liquid chromatography to investigate the uniformity. The specific detection conditions were as follows:

[0069] Chromatographic column: an octadecylsilane bonded silica gel chromatographic column (in this experimental example, Waters ACQUITY UPLC HSS T3, 2.1 mm × 100 mm, 1.8 μm) was used;

[0070] Mobile phase A: Prepared by adding 6 g of sodium perchlorate, 2.0 ml of phosphoric acid and 2 L of water;

[0071] Mobile phase B: 6 g of sodium perchlorate, 2.0 ml of phosphoric acid, 101 ml of methanol, 1107 ml of acetonitrile, and 800 ml of water;

[0072] Detection wavelength: 280nm;

[0073] Flow rate: 0.3ml / min;

[0074] Column temperature: 25°C;

[0075] Sample chamber temperature: 9°C;

[0076] Injection volume: 3 μl;

[0077] The elution program conditions are as follows:

[0078] Time / min Mobile phase A%, v / v Mobile phase B%, v / v 0 51 49 15 51 49 21 0 100 23 51 49 25 51 49

[0079] Reference solution: Take an appropriate amount of lanreotide acetate reference, weigh accurately, and dissolve in 0.1 mol / L acetic acid aqueous solution to prepare a solution containing approximately 0.6 mg of lanreotide free base per 1 ml.

[0080] Test solution: Take one sample each prepared according to the methods of Examples 1 to 3 and Comparative Examples 1 to 2, take out the contents, accurately weigh them, add 0.1 mol / L acetic acid aqueous solution to dissolve and dilute them to prepare a solution containing about 0.6 mg of lanreotide free base per 1 ml.

[0081] The concentration of lanreotide free base in each sample was calculated by peak area according to the external standard method and the RSD was calculated. The results are shown in Table 1.

[0082] Table 1 Uniformity inspection results

[0083]

[0084]

[0085] It is known that the smaller the RSD value of the concentration among 10 samples, the more uniform the sample mixing is. From the results in Table 1, it can be seen that the RSD of the concentration among 10 samples of the products prepared by the methods of Examples 1, 2, and 3 of the present invention are 0.42%, 0.24%, and 0.32%, respectively, all <0.5%; while the RSD of the concentration among 10 samples of the products prepared by the methods of Comparative Examples 1 and 2 are 2.8% and 3.3%, respectively, both around 3%, indicating that the product prepared by the method of the present invention is more uniform than that prepared by the prior art.

[0086] 2. Release curve investigation

[0087] The absorbance at different time points was measured by UV-spectrophotometer at a wavelength of 278 nm using a conventional quartz cuvette, and the cumulative dissolution of lanreotide free base at different time points was calculated to investigate the release effect of the product prepared by the method of the present invention. The specific method is as follows:

[0088] Preparation of reference solution: Weigh an appropriate amount of lanreotide acetate reference substance, dissolve and dilute with 0.9% sodium chloride aqueous solution to prepare a series of reference solutions containing approximately 3ug, 9ug, 15ug, 30ug, 60ug, 90ug, 120ug, and 150ug of lanreotide free base per 1ml.

[0089] The circulation pool uses a standard pool with an inner diameter of 22.6mm. A ruby ​​with a diameter of 5mm is installed at the bottom of the circulation pool cone, covered with about 5g of glass beads with a diameter of 1mm. The top cover of the circulation pool is equipped with a GF / F ultrafine glass fiber filter membrane with a pore size of 0.7μm.

[0090] Preparation of dissolution samples: Take one sample each prepared according to the methods of Examples 1 to 3 and Comparative Examples 1 to 2 and one bottle of the original marketed preparation of lanreotide acetate (trade name: somadulin), bring them to room temperature, inject the contents onto the glass beads, and accurately weigh the amount of sample added.

[0091] Other dissolution conditions of the flow cell:

[0092] Dissolution medium concentration: pH 7.4 phosphate buffer;

[0093] Flow rate: 8ml / min;

[0094] Sampling volume: 4ml;

[0095] Sampling time points: 165min, 300min, 555min, 855min, 1155min, 1455min, 1800min;

[0096] The dissolution samples at the above-mentioned time points were directly measured, and the cumulative release percentage Pi(t) of lanreotide free base at each time point was calculated according to the following formula:

[0097]

[0098] In the above formula:

[0099] Pi(t): cumulative release percentage of lanreotide free base at each time point, %;

[0100] Cn: Concentration of lanreotide free base taken out at each time point, μg / ml;

[0101] V1: fixed sampling volume at each time point, ml;

[0102] V2: volume of dissolution medium, ml;

[0103] Mi: The amount of lanreotide free base in the flow cell, mg.

[0104] Among them, the amount Mi of lanreotide free base in the flow cell is calculated as follows:

[0105]

[0106] In the above formula:

[0107] Mi: amount of lanreotide free base in the flow cell (mg);

[0108] T: lanreotide free base concentration (%, w / w);

[0109] Wi: weight of dissolved sample in the flow cell (mg);

[0110] Among them, the calculation formula of the concentration Cn of lanreotide free base taken out at each time point is:

[0111]

[0112] In the above formula:

[0113] Cn: Concentration of lanreotide free base taken out at each time point, μg / ml;

[0114] yn: absorbance of the sample taken at each time point, where the absorbance of each point of the standard curve and the test solution is the absorbance after deducting the absorbance of the dissolution medium;

[0115] b: intercept of the linear equation obtained from the standard curve;

[0116] a: Slope of the linear equation obtained from the standard curve.

[0117] The results are shown in Table 2 below.

[0118] Table 2 Release curve investigation results

[0119]

[0120]

[0121] The release similarity factor f2 is a conventional method for evaluating whether the release between samples is consistent. If f2>50, the release behavior is considered to be similar. From the results of Table 2, it can be seen that the release similarity factors f2 of the products prepared by the methods of Example 1, Example 2, and Example 3 of the present invention and the original preparation are 88, 87, and 77, respectively, all of which are>50, indicating that the release effect of the product prepared by the method of the present invention is consistent with that of the original preparation.

Claims

1. A method for preparing a lanreotide acetate sustained-release composition, characterized in that: The steps include: a. dissolving lanreotide acetate in water to prepare an aqueous solution; b. Concentrate the aqueous solution obtained in step a under reduced pressure until the concentration is 20-28% (w / w) based on lanreotide free base.

2. The preparation method according to claim 1, characterized in that: Step b is concentrated to a concentration of 23% to 26%, w / w, based on lanreotide free base; preferably, step b is concentrated to a concentration of 24.6%, w / w, based on lanreotide free base.

3. The preparation method according to claim 1 or 2, characterized in that: Step b: concentrating the aqueous solution into a semi-solid viscous gel state.

4. The preparation method according to claim 1, characterized in that: The aqueous solution obtained in step a has a concentration of 18 to 22 mg / ml as lanreotide free base; preferably, the aqueous solution obtained in step a has a concentration of 20 mg / ml as lanreotide free base.

5. The preparation method according to claim 1, characterized in that: The vacuum degree of the reduced pressure concentration in step b is 30-100 Pa; preferably, the vacuum degree of the reduced pressure concentration in step b is 50 Pa.

6. The preparation method according to claim 1, characterized in that: Step b is concentrated under reduced pressure at 30-70°C; preferably, step b is concentrated under reduced pressure at 40-60°C; further preferably, step b is concentrated under reduced pressure at 50°C.

7. The preparation method as claimed in claim 1, characterized in that: Before step b, the method further includes filtering the aqueous solution obtained in step a; preferably, filtering is performed using two-stage 0.22 μm sterilizing filters.

8. The lanreotide acetate sustained-release composition obtained according to the preparation method according to any one of claims 1 to 7.

9. Use of the lanreotide acetate sustained-release composition according to claim 8 in the preparation of an injection; preferably, the injection is a subcutaneous injection.

10. Use of the lanreotide acetate sustained-release composition according to claim 8 in the preparation of a medicament for treating acromegaly or gastroenteropancreatic neuroendocrine tumors or carcinoid syndrome.

Citation Information

Cited By

  • Process for preparation of pharmaceutical compositions for delayed release of somatostatin analogs

    CN119700927A

  • Preparation method of injectable sustained-release gel medicine as well as product and application of injectable sustained-release gel medicine

    CN121265520A